Within the framework of the 11th GEICO Symposium, the Spanish Group for Gynecological Cancer Research celebrates its 25th anniversary, emphasizing its ongoing commitment to research in the field of gynecological oncology. Since its foundation in 1999, GEICO has played a crucial role in advancing the treatment of various types of gynecological cancers, including ovarian, endometrial, and cervical cancer. Over the past two and a half decades, the group has not only promoted the training of specialists but has also established itself as a reference in both national and international settings, thanks to its innovative studies.
Dr. Antonio González-Martín, president of GEICO, has highlighted the importance of identifying biomarkers and implementing targeted therapies, which have allowed for personalized treatments and significant improvements in patient prognosis. “Some of these trials have increased the cure rates of our patients and have changed treatment standards,” Dr. González states, emphasizing the group’s essential role in conducting clinical trials with new therapies.
GEICO’s collaboration with international networks such as ENGOT and GCIG has expanded its influence beyond Spain, facilitating its participation in high-impact multicenter trials. The active presence of its members in world-renowned conferences and their authorship in clinical trials highlight their contribution to the global discussion on new therapeutic strategies.
Beyond clinical trials, GEICO has adopted a comprehensive approach that includes continuous medical education, scientific exchanges, and the training of experts in gynecological oncology. The group has organized symposia and training courses to ensure that all professionals involved in the treatment of gynecological tumors have access to the latest scientific advances. Additionally, the clinical guidelines developed by GEICO have become key references for the treatment of gynecological cancer.
As a non-profit organization, GEICO has established itself as a leader in oncological research in Spain, promoting high-quality clinical studies and fostering scientific cooperation. Its main objectives include the development and coordination of clinical trials, the generation of innovative knowledge, and the contribution to continuous growth in the field of gynecological oncology, with the aim of offering patients the best available therapeutic options.
Looking towards the future, GEICO is committed to continuing to innovate and improve the quality of life and survival rates of patients with gynecological cancer, aspiring to continue its work for another 25 years or more.
via: MiMub in Spanish
